Ray Patnaude – Page 7 – Safe Biologics

GaBI Journal Publishes Critical Review of Canadian Substitution Policies

September 30, 2021

On September 30th, the Generics and Biosimilars Initiative published GaBI Journal, Volume 10, 2021, Issue 3, containing a new whitepaper by ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider. The paper is entitled “A Critical Review of Substitution Policy for Biosimilars in Canada” and highlights the stark contrast between the forced-substitution policies recently enacted by some Canadian provinces and the pro-competition policies […]

September 2021

September 30, 2021

ASBM Welcomes Ralph McKibbin, MD as Chairman In a Full Member Call September 9th, ASBM introduced gastroenterologist Ralph McKibbin, MD, FACP, FACG, AGAF as the organization’s incoming chairman. Dr. McKibbin began his three year term on September 1st, succeeding outgoing chair Madelaine Feldman, MD, FACR. Dr. McKibbin is the fourth chairman since ASBM was […]

July-August 2021 Newsletter

September 29, 2021

Madelaine Feldman Completes Term as ASBM Chair On August 31st, ASBM Chair Madelaine Feldman, MD, FACR completed her term as ASBM Chair. ASBM Executive Director Michael Reilly praised Dr. Feldman’s leadership: Dr. Feldman led ASBM during a difficult time, keeping ASBM engaged on important biosimilar policy issues during the COVID-19 pandemic. As […]

ASBM Presents to Malta Medicines Authority

September 8, 2021

On August 26th, ASBM’s Advisory Board Chair Philip Schneider gave a series of presentations at a Biosimilars Forum hosted by the Malta Medicines Authority in Valetta, Malta. Dr. Schneider provided an extensive overview of multiple topics related to biosimilars, including: Biosimilars: General Concepts (20 min) View here Biologic Nomenclature and the Importance of Non-proprietary Names […]

ASBM Whitepaper Offers Critical Review of Canadian Substitution Policies

August 22, 2021

On August 22nd, the Journal of the Generics and Biosimilars Journal (GaBI Journal) published a new whitepaper by ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider. The paper is entitled “A Critical Review of Substitution Policy for Biosimilars in Canada” and highlights the stark contrast between the forced-substitution policies recently enacted by some Canadian provinces and the pro-competition […]

ASBM Letter to Congress Urges Level Playing Field for All Biologics

July 31, 2021

On July 28th, ASBM sent a letter to Congressional leaders expressing our opposition to H.R.2815, the BIOSIM Act, a bill “to amend title XVIII of the Social Security Act to provide for a temporary payment increase under the Medicare program for certain biosimilar biological products to encourage the development and use of such products.” The bill proposes […]

FDA Approves First Interchangable Biosimilar Insulin

July 28, 2021

On July 28th, the U.S. Food and Drug Administration (FDA) announced the long-awaited approved of the first interchangeable biosimilar, Mylan’s SemgleeⓇ. Under the Biologic Price Competition and Innovation Act (BPCIA) of 2009, which governs U.S. biosimilar development, an interchangeable biosimilar may be substituted in place of its reference product (in this case, Sanofi’s insulin glargine LantusⓇ) at the pharmacy without the […]

ASBM Presents CE Course on the Biosimilar Market in 2021

July 27, 2021

On July 27th, ASBM Advisory Board Chair Philip Schneider presented an online Continuing Education (CE) course entitled the “The State of the Biosimilars Market in 2021”. The course was presented in conjunction with Long Island University College of Pharmacy (LIU-Pharmacy) and viewed by more than 150 pharmacists, mostly from the New York area. The presentation looked […]

AMA Passes ACR-led Resolution Opposing Paying Patients to Switch Treatments

July 12, 2021

On June 15th, the American Medical Association (AMA) passed a resolution opposing the practice of insurers providing financial incentives for patients to switch to a payer-preferred treatment. The resolution was drafted by the American Colloge of Rheumatology (ACR) and passed during the AMA’s June 2021 Special Meeting. The ACR drafted the resolution after learning Cigna was notifying patients […]

ASBM Presents on Patient & Physician Perspectives at 15th Biosimilars Congregation

July 12, 2021

On June 24th, ASBM Executive Director Michael Reilly presented at the 15th Biosimilars Congregation. The event was organized to provide insight into the current state of play in the EU with respect to biosimilars and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. It also highlighted […]